Astellas starts Phase 3 trial of setidegrasib versus docetaxel in KRAS G12D — mutated NSCLC
Astellas dosed the first patient in a Phase 3 trial of setidegrasib for previously treated KRAS G12D-mutated advanced NSCLC. Study pits the investigational KRAS G12D protein degrader against docetaxel, targeting patients who progressed on platinum chemotherapy and CPI. Trial focuses on whether setidegrasib can delay di